Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony agresywny chłoniak B-komórkowy (określonego typu)
- •Chłoniak, który powrócił po leczeniu lub nie reaguje na poprzednie leczenie
- •Wcześniejsze leczenie musiało zawierać co najmniej jeden schemat z antracyklinami i przeciwciałami anty-CD20
- •Brak pierwotnego chłoniaka śródpiersiowego dużych komórek B
✗ Disqualifies
- •Ciąża lub potencjalna ciąża (test ciążowy wymagany przed rozpoczęciem leczenia)
- •Kobiety w wieku rozrodczym muszą używać skutecznej antykoncepcji podczas badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (86)
Banner University Medical Center - Tucson
Tucson, United States
University of Arizona Cancer Center-North Campus
Tucson, United States
Cedars-Sinai Medical Center
Los Angeles, United States
Smilow Cancer Hospital-Derby Care Center
Derby, United States
Smilow Cancer Hospital Care Center - Guilford
Guilford, United States
Yale University
New Haven, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Northwestern University
Chicago, United States
Carle at The Riverfront
Danville, United States
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, United States
Carle Physician Group-Effingham
Effingham, United States
Northwestern Medicine Cancer Center Delnor
Geneva, United States
Northwestern Medicine Glenview Outpatient Center
Glenview, United States
Northwestern Medicine Grayslake Outpatient Center
Grayslake, United States
Northwestern Medicine Lake Forest Hospital
Lake Forest, United States
Carle Physician Group-Mattoon/Charleston
Mattoon, United States
Carle BroMenn Medical Center
Normal, United States
Carle Cancer Institute Normal
Normal, United States
Northwestern Medicine Oak Brook
Oak Brook, United States
Northwestern Medicine Orland Park
Orland Park, United States
Memorial Hospital East
Shiloh, United States
Carle Cancer Center
Urbana, United States
Northwestern Medicine Cancer Center Warrenville
Warrenville, United States
Mary Greeley Medical Center
Ames, United States
McFarland Clinic - Ames
Ames, United States
McFarland Clinic - Boone
Boone, United States
Mercy Hospital
Cedar Rapids, United States
Oncology Associates at Mercy Medical Center
Cedar Rapids, United States
McFarland Clinic - Trinity Cancer Center
Fort Dodge, United States
McFarland Clinic - Jefferson
Jefferson, United States
McFarland Clinic - Marshalltown
Marshalltown, United States
Ochsner Medical Center Jefferson
New Orleans, United States
National Institutes of Health Clinical Center
Bethesda, United States
Essentia Health Saint Joseph's Medical Center
Brainerd, United States
Essentia Health - Deer River Clinic
Deer River, United States
Essentia Health Cancer Center
Duluth, United States
Essentia Health Hibbing Clinic
Hibbing, United States
Essentia Health Sandstone
Sandstone, United States
Essentia Health Virginia Clinic
Virginia, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
Community Hospital of Anaconda
Anaconda, United States
Billings Clinic Cancer Center
Billings, United States
Bozeman Health Deaconess Hospital
Bozeman, United States
Benefis Sletten Cancer Institute
Great Falls, United States
Community Medical Center
Missoula, United States
Nebraska Medicine-Bellevue
Bellevue, United States
Nebraska Medicine-Village Pointe
Omaha, United States
University of Nebraska Medical Center
Omaha, United States
Duke University Medical Center
Durham, United States
Essentia Health Cancer Center-South University Clinic
Fargo, United States
Aultman Health Foundation
Canton, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Providence Newberg Medical Center
Newberg, United States
Providence Willamette Falls Medical Center
Oregon City, United States
Providence Portland Medical Center
Portland, United States
Providence Saint Vincent Medical Center
Portland, United States
Thomas Jefferson University Hospital
Philadelphia, United States
University of Vermont Medical Center
Burlington, United States
University of Vermont and State Agricultural College
Burlington, United States
University of Virginia Cancer Center
Charlottesville, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Swedish Medical Center-First Hill
Seattle, United States
Duluth Clinic Ashland
Ashland, United States
Mercyhealth Hospital and Cancer Center - Janesville
Janesville, United States
Gundersen Lutheran Medical Center
La Crosse, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, United States
Froedtert Menomonee Falls Hospital
Menomonee Falls, United States
Medical College of Wisconsin
Milwaukee, United States
ProHealth D N Greenwald Center
Mukwonago, United States
Froedtert and MCW Moorland Reserve Health Center
New Berlin, United States
Drexel Town Square Health Center
Oak Creek, United States
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, United States
Essentia Health-Spooner Clinic
Spooner, United States
Essentia Health Saint Mary's Hospital - Superior
Superior, United States
UW Cancer Center at ProHealth Care
Waukesha, United States
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, United States
Trial contact
Site Public Contact
Justin M. Darrah
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shalin Kothari
PRINCIPAL_INVESTIGATOR
Site Public Contact
Reem Karmali
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Brad S. Kahl
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joseph J. Merchant
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Deborah W. Wilbur
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Ashley D. Staton
PRINCIPAL_INVESTIGATOR
Site Public Contact
Christopher J. Melani
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bret E. Friday
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Snegha Ananth
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Disha Dalela
PRINCIPAL_INVESTIGATOR
Site Public Contact
Aarthi Rajkumar
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kathryn Lurain
PRINCIPAL_INVESTIGATOR
Site Public Contact
Muhammad Salman Faisal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alison K. Conlin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michael Wysota
PRINCIPAL_INVESTIGATOR
Site Public Contact
James N. Gerson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Craig A. Portell
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bruce O. Hough
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Emily G. Robinson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kurt Oettel
PRINCIPAL_INVESTIGATOR
Site Public Contact
Priyanka Pophali
PRINCIPAL_INVESTIGATOR
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.